These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23119228)

  • 21. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
    Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
    Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
    Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Captopril mitigates splenomegaly and myelofibrosis in the Gata1
    Corey SJ; Jha J; McCart EA; Rittase WB; George J; Mattapallil JJ; Mehta H; Ognoon M; Bylicky MA; Summers TA; Day RM
    J Cell Mol Med; 2018 Sep; 22(9):4274-4282. PubMed ID: 29971909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
    Marcellino BK; Verstovsek S; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis.
    Wang Z; Jin X; Zeng J; Xiong Z; Chen X
    Ann Hematol; 2024 Mar; ():. PubMed ID: 38494551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging therapies in primary myelofibrosis.
    Ayyappan S; Janakiram M; Raghupathy R
    Cardiovasc Hematol Disord Drug Targets; 2012 Sep; 12(1):6-20. PubMed ID: 22746348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
    Ostojic A; Vrhovac R; Verstovsek S
    Ther Clin Risk Manag; 2012; 8():95-103. PubMed ID: 22399854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond JAK inhibitor therapy in myelofibrosis.
    Odenike O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stem cell transplant for the treatment of myelofibrosis.
    Mannelli L; Guglielmelli P; Vannucchi AM
    Expert Rev Hematol; 2020 Apr; 13(4):363-374. PubMed ID: 32077336
    [No Abstract]   [Full Text] [Related]  

  • 32. Management of Myelofibrosis: from Diagnosis to New Target Therapies.
    Iurlo A; Cattaneo D; Bucelli C
    Curr Treat Options Oncol; 2020 Apr; 21(6):46. PubMed ID: 32350623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.
    Fauble V; Leis J; Mesa RA
    Leuk Suppl; 2012 May; 1(Suppl 1):S2-7. PubMed ID: 27175229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.
    Barosi G; Rosti V; Gale RP
    Onco Targets Ther; 2015; 8():1091-102. PubMed ID: 26056473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How I treat symptomatic splenomegaly in patients with myelofibrosis.
    Mesa RA
    Blood; 2009 May; 113(22):5394-400. PubMed ID: 19332765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
    Liu JX; Chen W; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelofibrosis and allogeneic transplantation: critical points and challenges.
    Ranalli P; Natale A; Guardalupi F; Santarone S; Cantò C; La Barba G; Di Ianni M
    Front Oncol; 2024; 14():1396435. PubMed ID: 38966064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
    Ecsedi M; Schmohl J; Zeiser R; Drexler B; Halter J; Medinger M; Duyster J; Kanz L; Passweg J; Finke J; Bethge W; Lengerke C
    Ann Hematol; 2016 Oct; 95(10):1627-36. PubMed ID: 27480090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.